Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma

NCT07093073 | Recruiting Phase 1

• 1 other identifier: U01
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-arm, open-label clinical study evaluating the efficacy and safety of U01 (ssCART-19) in patients with relapsed or refractory B-cell lymphoma.

Conditions

B Cell Lymphoma

Keywords

CD19; ssCART-19

Outcome Measures

Primary Outcomes (5)

• Incidence of Adverse events after U01 CAR-T cells infusion [Safety and Tolerability]

  An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

  28 days post administration of ssCART-19

• Objective Response Rate (ORR), as assessed by Investigators

  The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Remission (CR) or Partial Remission(PR)

  2 years post CAR T cell infusion

• Duration of response (DOR)

  Duration of response (DOR) is defined as the time from the first documented objective response to the first documented disease progression or death.

  2 years post CAR T cell infusion

• Overall survival (OS)

  Overall Survival (OS) was defined as the time from the date of first infusion of U01 to the date of death due to any cause.

  2 years post CAR T cell infusion

• Progression-free survival (PFS)

  Progression-free survival (PFS) was defined as the time from the date of infusion to the earliest date of the first objective documentation of progressive disease (PD) or death due to any cause.

  2 years post CAR T cell infusion

Secondary Outcomes (4)

• Pharmacokinetics of ssCART-19

  2 years post CAR T cell infusion

• Pharmacokinetics of ssCART-19

  2 years post CAR T cell infusion

• Pharmacokinetics of ssCART-19

  2 years post CAR T cell infusion

• Pharmacodynamics of ssCART-19

  2 years post CAR T cell infusion

Study Arms (1)

U01(ssCART-19) CAR-T cells

EXPERIMENTAL

CD19-targeted CAR-T cells engineered with an IL-6 silencing element

Drug: ssCART-19

Interventions

ssCART-19 DRUG

Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.

U01(ssCART-19) CAR-T cells

Eligibility Criteria

• Age: 2 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntary written informed consent obtained from the participant (or legal guardian) with good compliance expected throughout the study.
• All of the following conditions must be met:
• Age 2-75 years at informed consent; both sexes eligible. For minors (≤18 years), consent must be provided by a parent/legal guardian; minors able to sign must co-sign with their guardian.
• Histologically confirmed B-cell lymphoma per the 2024 v3 NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas.
• Prior therapy requirements:
• Failure to achieve PR after first-line therapy, OR relapse within 12 months after first-line therapy; or Relapsed/refractory after second-line therapy (one standard chemo-regimen + one salvage regimen).
• Prior regimens must have included anti-CD20 monoclonal antibody (unless documented CD20-negative tumor) and an anthracycline-containing regimen. In addition, at least one of the following must apply:
• i. Ineligible for autologous hematopoietic stem-cell transplantation (ASCT); ii. Refusal of ASCT; iii. Relapse after ASCT. d) Disease status at screening:
• Relapse: progression after prior PR or CR.
• Refractory: i. PD during/after last therapy, or best response ≤SD lasting \<6 months; OR ii. Relapse or progression after ASCT (biopsy-proven), including relapse/PD ≤12 months post-ASCT or lack of response (SD/PD) to salvage therapy after ASCT.
• Tumor tissue (archival or fresh) positive for CD19 by IHC; pathology report within 6 months preferred.
• ≥1 measurable lesion per Lugano 2014 response criteria.
• ECOG performance status 0-3.
• Adequate marrow reserve: ALC ≥0.3 × 10⁹/L; PLT ≥30 × 10⁹/L (transfusion permitted).
• Adequate organ function:

You may not qualify if:

• Concurrent malignancy other than the study indication, except for carcinoma in situ or any malignancy with a disease-free interval ≥3 years.
• Presence of any of the following:• Positive HBe-Ab and/or HBc-Ab with HBV-DNA above the lower limit of quantification;• Positive HCV-Ab with HCV-RNA above the lower limit of quantification;• Positive Treponema pallidum antibody (TP-Ab);• Positive HIV antibody.
• Active bacterial, fungal, viral, mycoplasmal, or other infection deemed uncontrollable by the investigator.
• History or current clinically significant CNS disorder unrelated to lymphoma-e.g., seizure disorder, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any CNS autoimmune disease-that the investigator considers uncontrolled.
• Within 12 months before informed consent: percutaneous coronary intervention (angioplasty or stent placement), NYHA Class III-IV congestive heart failure, myocardial infarction, unstable angina, or other clinically significant cardiac history judged by the investigator; or QTc \>480 ms (Fridericia correction) or LVEF \<50 % by echocardiography at screening.
• Known primary immunodeficiency.
• History of severe immediate hypersensitivity to any study drug.
• Receipt of any live vaccine within 6 weeks before screening.
• Pregnant or breastfeeding women.
• Active autoimmune disease requiring systemic immunosuppressive therapy.
• Participation in any other interventional clinical trial within 30 days before signing informed consent.
• Any condition that, in the investigator's opinion, renders the subject unsuitable for study participation.

Sponsors & Collaborators

• Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd: lead

Study Sites (1)

Tongji Hospital of Tongji University

Shanghai, China

RECRUITING

MeSH Terms

Conditions

Lymphoma, B-Cell

Condition Hierarchy (Ancestors)

Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Wenjun Zhang, Ph.D.

  Tongji Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Wenjun Zhang, Ph.D

CONTACT

13918803148; zhangwenjun@tongji.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 21, 2025
• First Posted: July 30, 2025
• Study Start: January 23, 2025
• Primary Completion (Estimated): January 31, 2027
• Study Completion (Estimated): January 31, 2029
• Last Updated: May 6, 2026

Record last verified: 2025-09

Locations

CN (1)